Comparative effectiveness research: a proposal for a new NHMRC funding streamZALCBERG, John R.Medical journal of Australia. 2012, Vol 196, Num 1, pp 22-23, issn 0025-729X, 2 p.Article

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours : Lessons from the phase 3 trialsPATEL, Shreyaskumar; ZALCBERG, John R.European journal of cancer (1990). 2008, Vol 44, Num 4, pp 501-509, issn 0959-8049, 9 p.Article

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialMITTMANN, Nicole; AU, Heather-Jane; FINDLAY, Brian et al.Journal of the National Cancer Institute. 2009, Vol 101, Num 17, pp 1182-1192, issn 0027-8874, 11 p.Article

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugsBAKER, Emma K; JOHNSTONE, Ricky W; ZALCBERG, John R et al.Oncogene (Basingstoke). 2005, Vol 24, Num 54, pp 8061-8075, issn 0950-9232, 15 p.Article

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal CancerKARAPETIS, Christos S; KHAMBATA-FORD, Shirin; PRICE, Timothy J et al.The New England journal of medicine. 2008, Vol 359, Num 17, pp 1757-1765, issn 0028-4793, 9 p.Article

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer―Results from NCIC CTG/AGITG CO.17KARAPETIS, Christos S; JONKER, Derek; PRICE, Timothy J et al.Clinical cancer research (Print). 2014, Vol 20, Num 3, pp 744-753, issn 1078-0432, 10 p.Article

Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 TrialSIU, Lillian L; SHAPIRO, Jeremy D; NOTT, Louise M et al.Journal of clinical oncology. 2013, Vol 31, Num 19, pp 2477-2484, issn 0732-183X, 8 p.Article

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabDE ROOCK, Wendy; JONKER, Derek J; VAN CUTSEM, Eric et al.JAMA, the journal of the American Medical Association. 2010, Vol 304, Num 16, pp 1812-1820, issn 0098-7484, 9 p.Article

Quality of Life in Patients With K-RAS Wild-Type Colorectal Cancer: The CO.20 Phase 3 Randomized TrialRINGASH, Jolie; AU, Heather-Jane; ALCINDOR, Thierry et al.Cancer. 2014, Vol 120, Num 2, pp 181-189, issn 0008-543X, 9 p.Article

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX studyCARTER, Hannah E; ZANNINO, Diana; SIMES, R. John et al.European journal of cancer (1990). 2014, Vol 50, Num 3, pp 535-543, issn 0959-8049, 9 p.Article

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyTEBBUTT, Niall C; WILSON, Kate; FORGESON, Garry et al.Journal of clinical oncology. 2010, Vol 28, Num 19, pp 3191-3198, issn 0732-183X, 8 p.Article

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgZALCBERG, John R; VERWEIJ, Jaap; CASALI, Paolo G et al.European journal of cancer (1990). 2005, Vol 41, Num 12, pp 1751-1757, issn 0959-8049, 7 p.Article

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer ― Differential treatment strategies for subtypes of early gastroesophageal cancerLUTZ, Manfred P; ZALCBERG, John R; JANSEN, Edwin P. M et al.European journal of cancer (1990). 2012, Vol 48, Num 16, pp 2941-2953, issn 0959-8049, 13 p.Article

To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment OptionMILESHKIN, Linda; SCHOFIELD, Penelope E; JEFFORD, Michael et al.Journal of clinical oncology. 2009, Vol 27, Num 34, pp 5830-5837, issn 0732-183X, 8 p.Article

Cetuximab for the treatment of colorectal cancerJONKER, Derek J; O'CALLAGHAN, Chris J; TEBBUTT, Niall C et al.The New England journal of medicine. 2007, Vol 357, Num 20, pp 2040-2048, issn 0028-4793, 9 p.Article